Our top pick for
Enzo Biochem, Inc is a diagnostics & research business based in the US. Enzo Biochem shares (ENZ) are listed on the NYSE and all prices are listed in US Dollars. Enzo Biochem employs 408 staff and has a trailing 12-month revenue of around USD$84.5 million.
|Latest market close||USD$2.55|
|52-week range||USD$1.56 - USD$3.68|
|50-day moving average||USD$2.1953|
|200-day moving average||USD$2.2718|
|Wall St. target price||USD$5.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.03|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-5.20%|
|1 month (2020-12-17)||4.51%|
|3 months (2020-10-15)||19.72%|
|6 months (2020-07-15)||1.59%|
|1 year (2020-01-15)||-0.78%|
|2 years (2019-01-15)||-21.78%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||4.52|
Valuing Enzo Biochem stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enzo Biochem's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enzo Biochem's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 101x. In other words, Enzo Biochem shares trade at around 101x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$84.5 million|
|Gross profit TTM||USD$23.8 million|
|Return on assets TTM||-11.35%|
|Return on equity TTM||-29.96%|
|Market capitalisation||USD$110.2 million|
TTM: trailing 12 months
There are currently 2.0 million Enzo Biochem shares held short by investors – that's known as Enzo Biochem's "short interest". This figure is 2% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Enzo Biochem shares can be evaluated.
Enzo Biochem's "short interest ratio" (SIR) is the quantity of Enzo Biochem shares currently shorted divided by the average quantity of Enzo Biochem shares traded daily (recently around 333115.5143339). Enzo Biochem's SIR currently stands at 5.93. In other words for every 100,000 Enzo Biochem shares traded daily on the market, roughly 5930 shares are currently held short.
However Enzo Biochem's short interest can also be evaluated against the total number of Enzo Biochem shares, or, against the total number of tradable Enzo Biochem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enzo Biochem's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Enzo Biochem shares in existence, roughly 40 shares are currently held short) or 0.0509% of the tradable shares (for every 100,000 tradable Enzo Biochem shares, roughly 51 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Enzo Biochem.
Find out more about how you can short Enzo Biochem stock.
We're not expecting Enzo Biochem to pay a dividend over the next 12 months.
Enzo Biochem's shares were split on a 105:100 basis on 21 October 2004. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your Enzo Biochem shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Enzo Biochem shares which in turn could have impacted Enzo Biochem's share price.
Over the last 12 months, Enzo Biochem's shares have ranged in value from as little as $1.56 up to $3.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enzo Biochem's is 0.8604. This would suggest that Enzo Biochem's shares are less volatile than average (for this exchange).
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ?STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.